Equillium (EQ) FY2025 10-K Risk Factors: 23 New, 21 Dropped

What the changes say

Pipeline shifted from itolizumab to new product candidates EQ504 and EQ302, requiring substantial additional capital.

What changed since the prior 10-K

New

NewRisks Related to Our Financial Position and Need for Additional Capital
We have and will continue to pursue sources of additional capital, including pursuant to the Open Market Sales AgreementSM, dated October 8, 2023, as amended August 3, 2025, with LifeSci Capital LLC, the 2023 ATM Facility, as well as other financing sources that may be available to us
The company lacks sufficient funds to complete clinical development of EQ504 and must raise substantial additional capital through stock sales or strategic transactions.
NewRisks Related to Our Financial Position and Need for Additional Capital
or other securities or through the entering into of alternative strategic transactions, the terms of which may require us to divest one or more of our product candidates, or cause our stockholders to incur substantial dilution
Future funding needs depend on nonclinical and clinical studies for EQ504, EQ302, and preclinical drug candidates, impacted by macroeconomic factors and tariffs.
NewRisks Related to Our Financial Position and Need for Additional Capital
the cost, timing and impact of our new cryptocurrency treasury reserve strategy, if implemented
The company replaced Jefferies LLC with LifeSci Capital LLC for its ATM facility to sell up to $75.0 million in common stock.
NewRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
We are highly dependent on the successful planned or future development of our current product candidates, EQ504 and EQ302, and we may not be able to obtain regulatory or marketing approval of, or successfully commercialize, these product candidates in any of the indications for which we plan to develop them
Future success depends entirely on developing and commercializing current product candidates EQ504 and EQ302, which currently generate no revenue.
NewRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
maintaining a continued acceptable safety profile of our products, if and when approved
Delays in achieving an acceptable safety profile for products could prevent timely marketing approval and commercialization.
NewRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates in our planned or future clinical studies as well as in clinical studies, investigator-initiated studies and potential commercial usage
Undesirable side effects in clinical studies may force the company to abandon, limit, or modify the development of its product candidates.
NewRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
conditions that did not occur or went undetected in previous studies, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly
Identifying undesirable side effects post-approval could lead to product recalls, label warnings, REMS requirements, or patient lawsuits.
NewRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
rebates required by government healthcare programs or private payors, by any future laws limiting pharmaceutical prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States
Third-party payors are increasingly challenging drug prices, medical necessity, and cost-effectiveness, creating reimbursement uncertainty.
NewRisks Related to Manufacturing and Our Reliance on Third Parties
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects
New U.S. tariffs and international trade policies affecting the pharmaceutical industry may adversely affect business operations.
NewRisks Related to Manufacturing and Our Reliance on Third Parties
future clinical studies must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical studies, which would delay the marketing approval process
Failure to comply with cGMP regulations by third-party manufacturers or CROs may require the company to stop or repeat clinical studies.
NewRisks Related to Intellectual Property
whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries
There is no guarantee that owned or in-licensed patent applications will result in issued claims covering product candidates.
NewRisks Related to Employees, Managing Our Growth and Other Legal Matters
compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs
Violations of anti-corruption, anti-money laundering, or trade laws can result in substantial fines, criminal penalties, and debarment.
NewRisks Related to Ownership of our Common Stock
We have indemnity obligations and other responsibilities under the registration rights agreement and securities purchase agreement entered into with investors on August 12, 2025 and March 13, 2026. If these obligations are not met, we may be required to pay damages and indemnify the investors
NewRisks Related to Ownership of our Common Stock
provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors
NewRisks Related to Ownership of our Common Stock
Securities Act claims in state court, or both state and federal court, which could seriously harm our business, financial condition, results of operations, and prospects
NewRisks Related to Our Crypto Treasury Strategy
Cryptocurrencies are highly volatile assets, and fluctuations in the price of cryptocurrencies are likely to influence our financial results and the market price of our common stock
NewRisks Related to Our Crypto Treasury Strategy
We may use the net proceeds from any offering by the company to purchase cryptocurrencies, the price of which has been, and will likely continue to be, highly volatile
NewRisks Related to Our Crypto Treasury Strategy
Cryptocurrency and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertainty
NewRisks Related to Our Crypto Treasury Strategy
Cryptocurrency holdings are less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents
NewRisks Related to Our Crypto Treasury Strategy
We may face risks relating to the custody of our cryptocurrency, if any, including the loss or destruction of private keys required to access our cryptocurrency and cyberattacks or other data loss relating to our cryptocurrency
NewRisks Related to Our Crypto Treasury Strategy
Regulatory change reclassifying cryptocurrency as a security could lead to our classification as an “investment company” under the Investment Company Act of 1940, or the 1940 Act, and could adversely affect the market price of cryptocurrencies and the market price of our common stock
NewRisks Related to Our Crypto Treasury Strategy
our business and operations and may also require us to change the manner in which we conduct our business. We may also be subject to enforcement actions or penalties if our activities are deemed to violate applicable laws or regulations
NewRisks Related to Our Crypto Treasury Strategy
We do not currently have the expertise to implement our cryptocurrency treasury reserve strategy and may fail to identify qualified individuals or asset managers to develop and execute successful investment or trading strategies

Dropped

DroppedRisks Related to Our Financial Position and Need for Additional Capital
the cost associated with commercializing our product candidates if any are approved for commercial sale
DroppedRisks Related to Our Financial Position and Need for Additional Capital
Our corporate cash saving initiatives and the associated headcount reductions we implemented, and potential additional headcount reductions in the future, could disrupt our business, and may not achieve our intended objectives
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
revenues from sales of any biopharmaceutical products, and we may never be able to develop or commercialize a marketable biopharmaceutical product
Costs associated with commercializing product candidates under the 2023 ATM facility with Jefferies.
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
industry and market conditions generally
Corporate cash savings initiatives and headcount reductions following the termination of the Ono partnership.
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
If we do not achieve one or more of these factors in a timely manner, we could experience significant delays or an inability to successfully obtain marketing approval and commercialize our product candidates, which would materially harm our business
Need to build a commercial organization or marketing collaboration before selling products in the US.
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
Based on our current limited clinical experience with itolizumab (EQ001), expected adverse events include lymphopenia, injection site reactions, infusion-/injection-related reactions (including fever and headache), and other systemic hypersensitivity reactions including rash, urticaria, erythema, and pruritus
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
market acceptance of our product candidates. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock
Collaborator considerations of alternative product technologies and complex collaboration negotiations.
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
Our current product candidates and any future product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
Difficulty predicting timing and costs for first-in-class CD6 target itolizumab (EQ001).
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
We may not ultimately realize the potential benefits of orphan drug designation for itolizumab (EQ001) or, if we resume development activities, EQ101
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
Fast-track designation by the FDA may not actually lead to a faster development or regulatory review or approval process
DroppedRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition
DroppedRisks Related to Intellectual Property
We depend on intellectual property licensed from Biocon and termination of our license could result in the loss of significant rights, which would harm our business
DroppedRisks Related to Intellectual Property
the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners
DroppedRisks Related to Intellectual Property
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets
DroppedRisks Related to Employees, Managing Our Growth and Other Legal Matters
improve our operational, financial and management controls, reporting systems and procedures
DroppedRisks Related to Employees, Managing Our Growth and Other Legal Matters
States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer laws
Specific adverse events identified in itolizumab clinical programs such as lymphopenia and injection site reactions.
DroppedRisks Related to Employees, Managing Our Growth and Other Legal Matters
If we fail to comply with U.S. export control and economic sanctions, our business, financial condition and prospects may be materially and adversely affected
Market acceptance risks and potential abandonment of product candidates due to unexpected side effects.
DroppedRisks Related to Employees, Managing Our Growth and Other Legal Matters
authorizing activities relating to the commercialization of itolizumab (EQ001), or the Submission. We simultaneously requested that OFAC treat the Submission as a voluntary disclosure if OFAC concluded that our determination that the general license applies to itolizumab (EQ001) was in error
DroppedRisks Related to Ownership of our Common Stock
Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims
Risks of stock price volatility from differences between preliminary and final data or competitor disclosures.

Reworded

92% rewrittenRisks Related to Our Financial Position and Need for Additional Capital
and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment
Updated pipeline focus from itolizumab to EQ504 and EQ302, adding that expenses will increase substantially for larger clinical studies.
Was: failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment
78% rewrittenRisks Related to Our Crypto Treasury Strategy
Changes in tax laws or regulations that are applied adversely to us or our potential customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
Replaced reference to the 2017 Tax Cuts and Jobs Act with the enacted OBBBA tax reform impacting international tax and R&D amortization.
Was: Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
77% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
neither experimental nor investigational
Removed prior-year commentary regarding physician-administered injectables and separate reimbursement challenges for those products.
76% rewrittenRisks Related to Employees, Managing Our Growth and Other Legal Matters
We are highly dependent on the services of our key personnel
Updated executive titles, noting Bruce D. Steel serves as CEO and Stephen Connelly as President and Chief Scientific Officer, removing employee count.
76% rewrittenRisks Related to Ownership of our Common Stock
Raising additional equity capital may cause dilution to our stockholders, and raising additional equity or debt capital may restrict our operations or require us to relinquish rights to our technologies or product candidates
Added specific disclosures regarding gross proceeds of $30.0 million from an August 2025 private placement and $35.0 million from a March 2026 private placement.
Was: Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
74% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
Potential natural disasters, some possibly related to the increasing effects of climate change, could damage, destroy or disrupt clinical study sites, our office spaces, laboratories, and/or warehouses, which could have a significant negative impact on our operations
Added references to planned or future clinical studies regarding climate change and natural disaster disruptions.
73% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
Interim, topline or preliminary data from our planned or future clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
Updated wording from non-clinical to nonclinical studies regarding preliminary or topline data changes.
Was: Interim, topline or preliminary data from our clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
69% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations with respect to our current or future product candidates, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans
Minor stylistic and phrasing updates regarding the search for collaborators and capital needs.
66% rewrittenRisks Related to Ownership of our Common Stock
If there are substantial sales of shares of our common stock, the price of our common stock could decline
63% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
If market opportunities for our product candidates are smaller than we believe they are, our potential revenue may be adversely affected and our business may suffer
57% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
Even if we receive marketing approval, we may not be able to successfully commercialize any of our approved products due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell any of our approved products profitably
57% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
impacts and risks associated with global health epidemics or outbreaks
56% rewrittenRisks Related to Employees, Managing Our Growth and Other Legal Matters
individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA
Was: circumstances, we could be subject to penalties, including criminal penalties, if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA
52% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
We have limited experience in clinical development and have not successfully completed late-stage clinical studies or obtained regulatory approval for any product candidate
Was: We have limited experience in clinical development and have not successfully completed late-stage clinical studies or obtained regulatory approval of any product candidate
52% rewrittenRisks Related to Ownership of our Common Stock
The stock price of our common stock may be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment
44% rewrittenRisks Related to Intellectual Property
Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
42% rewrittenRisks Related to Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
40% rewrittenRisks Related to Ownership of our Common Stock
any other factors discussed in this report
37% rewrittenRisks Related to Intellectual Property
We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
35% rewrittenRisks Related to Employees, Managing Our Growth and Other Legal Matters
The ACA substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry
Was: The Affordable Care Act substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry
35% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated
34% rewrittenRisks Related to Ownership of our Common Stock
Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
30% rewrittenRisks Related to Our Crypto Treasury Strategy
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any product candidates that we may develop
29% rewrittenRisks Related to Our Crypto Treasury Strategy
the inability to commercialize any products that we may develop
28% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
If we experience delays or difficulties in enrolling patients in any future clinical studies, our receipt of necessary regulatory approval could be delayed or prevented
Was: If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical studies, or if we decide to enroll fewer subjects than the study protocol specifies for business reasons, our receipt of necessary regulatory approval could be delayed or prevented
27% rewrittenRisks Related to Employees, Managing Our Growth and Other Legal Matters
We conduct significant operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations will suffer
26% rewrittenRisks Related to our Business and to the Development and Regulatory Approval of our Product Candidates
We have and may in the future enter into partnerships or similar arrangements or otherwise monetize our pipeline through strategic transactions, which may harm our ability to realize a return, if any, on our investments and may increase our need for external funding
24% rewrittenRisks Related to Ownership of our Common Stock
any action asserting a claim against us that is governed by the internal-affairs doctrine
22% rewrittenRisks Related to Employees, Managing Our Growth and Other Legal Matters
We may be subject to applicable foreign, federal and state fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
22% rewrittenRisks Related to Our Financial Position and Need for Additional Capital
We have incurred significant losses since our inception, expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability

All 91 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Position and Need for Additional Capital

01We have incurred significant losses since our inception, expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability22% rewritten
02and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment92% rewritten
03We have and will continue to pursue sources of additional capital, including pursuant to the Open Market Sales AgreementSM, dated October 8, 2023, as amended August 3, 2025, with LifeSci Capital LLC, the 2023 ATM Facility, as well as other financing sources that may be available to usNew
04or other securities or through the entering into of alternative strategic transactions, the terms of which may require us to divest one or more of our product candidates, or cause our stockholders to incur substantial dilutionNew
05the cost, timing and impact of our new cryptocurrency treasury reserve strategy, if implementedNew

Risks Related to our Business and to the Development and Regulatory Approval of our Product Candidates

06We are highly dependent on the successful planned or future development of our current product candidates, EQ504 and EQ302, and we may not be able to obtain regulatory or marketing approval of, or successfully commercialize, these product candidates in any of the indications for which we plan to develop themNew
07We have and may in the future enter into partnerships or similar arrangements or otherwise monetize our pipeline through strategic transactions, which may harm our ability to realize a return, if any, on our investments and may increase our need for external funding26% rewritten
08We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations with respect to our current or future product candidates, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans69% rewritten
09We have limited experience in clinical development and have not successfully completed late-stage clinical studies or obtained regulatory approval for any product candidate52% rewritten
10maintaining a continued acceptable safety profile of our products, if and when approvedNew
11If we fail to develop or acquire other product candidates or products, our business and prospects would be limited
12Potential natural disasters, some possibly related to the increasing effects of climate change, could damage, destroy or disrupt clinical study sites, our office spaces, laboratories, and/or warehouses, which could have a significant negative impact on our operations74% rewritten
13The development and commercialization of biopharmaceutical products are subject to extensive regulation and we may not obtain regulatory approvals of our product candidates in any of the indications for which we plan to develop them, or any future product candidates, on a timely basis or at all
14may not accept a submission due to, among other reasons, the content or formatting of the submission
15Any delays in the commencement and completion, or any termination or suspension, of our planned or future clinical studies could result in increased costs to us, and delay or limit our ability to raise capital or generate revenue and adversely affect our commercial prospects
16If we experience delays or difficulties in enrolling patients in any future clinical studies, our receipt of necessary regulatory approval could be delayed or prevented28% rewritten
17impacts and risks associated with global health epidemics or outbreaks57% rewritten
18As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates in our planned or future clinical studies as well as in clinical studies, investigator-initiated studies and potential commercial usageNew
19conditions that did not occur or went undetected in previous studies, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantlyNew
20Interim, topline or preliminary data from our planned or future clinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data73% rewritten
21diminished protection of intellectual property in some countries
22Even if our product candidates receive marketing approval in any indication, they may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success
23the prevalence and severity of any side effects
24We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated35% rewritten
25If market opportunities for our product candidates are smaller than we believe they are, our potential revenue may be adversely affected and our business may suffer63% rewritten
26Even if we receive marketing approval, we may not be able to successfully commercialize any of our approved products due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell any of our approved products profitably57% rewritten
27rebates required by government healthcare programs or private payors, by any future laws limiting pharmaceutical prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United StatesNew
28neither experimental nor investigational77% rewritten

Risks Related to Manufacturing and Our Reliance on Third Parties

29International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
30future clinical studies must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical studies, which would delay the marketing approval processNew
31Our reliance on contracted parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks Related to Intellectual Property

32whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countriesNew
33In the future, we may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated
34Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
35We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
36If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates
37We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful
38Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
39We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
40We may not be able to protect our intellectual property rights throughout the world42% rewritten
41Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements44% rewritten
42We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed37% rewritten
43We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
44Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
45If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
46Intellectual property rights may not address all potential threats to our competitive advantage

Risks Related to Employees, Managing Our Growth and Other Legal Matters

47We are highly dependent on the services of our key personnel76% rewritten
48Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel
49Third-party expectations relating to environmental, social and governance factors may impose additional costs and expose us to new risks
50Our employees, clinical study investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
51individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA56% rewritten
52Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
53We conduct significant operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations will suffer27% rewritten
54Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may have a significant adverse effect on our business and results of operations
55The ACA substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry35% rewritten
56If any of our services providers are characterized as employees, we would be subject to employment and tax withholding liabilities and other additional costs
57We may be subject to applicable foreign, federal and state fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties22% rewritten
58compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programsNew

Risks Related to Ownership of our Common Stock

59The stock price of our common stock may be volatile or may decline regardless of our operating performance, and you could lose all or part of your investment52% rewritten
60any other factors discussed in this report40% rewritten
61Raising additional equity capital may cause dilution to our stockholders, and raising additional equity or debt capital may restrict our operations or require us to relinquish rights to our technologies or product candidates76% rewritten
62Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends
63If there are substantial sales of shares of our common stock, the price of our common stock could decline66% rewritten
64Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for other stockholders to sell shares of our common stock
65We have indemnity obligations and other responsibilities under the registration rights agreement and securities purchase agreement entered into with investors on August 12, 2025 and March 13, 2026. If these obligations are not met, we may be required to pay damages and indemnify the investorsNew
66The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval
67Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock34% rewritten
68provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directorsNew
69any action asserting a claim against us that is governed by the internal-affairs doctrine24% rewritten
70Securities Act claims in state court, or both state and federal court, which could seriously harm our business, financial condition, results of operations, and prospectsNew

Risks Related to Our Crypto Treasury Strategy

71Cryptocurrencies are highly volatile assets, and fluctuations in the price of cryptocurrencies are likely to influence our financial results and the market price of our common stockNew
72We may use the net proceeds from any offering by the company to purchase cryptocurrencies, the price of which has been, and will likely continue to be, highly volatileNew
73Cryptocurrency and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertaintyNew
74Cryptocurrency holdings are less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalentsNew
75We may face risks relating to the custody of our cryptocurrency, if any, including the loss or destruction of private keys required to access our cryptocurrency and cyberattacks or other data loss relating to our cryptocurrencyNew
76Regulatory change reclassifying cryptocurrency as a security could lead to our classification as an “investment company” under the Investment Company Act of 1940, or the 1940 Act, and could adversely affect the market price of cryptocurrencies and the market price of our common stockNew
77our business and operations and may also require us to change the manner in which we conduct our business. We may also be subject to enforcement actions or penalties if our activities are deemed to violate applicable laws or regulationsNew
78We do not currently have the expertise to implement our cryptocurrency treasury reserve strategy and may fail to identify qualified individuals or asset managers to develop and execute successful investment or trading strategiesNew
79As a public company in the United States, we incur significant legal and financial compliance costs and we are subject to the Sarbanes-Oxley Act. We can provide no assurance that we will, at all times, in the future be able to report that our internal controls over financial reporting are effective
80Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
81Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any product candidates that we may develop30% rewritten
82the inability to commercialize any products that we may develop29% rewritten
83Changes in tax laws or regulations that are applied adversely to us or our potential customers may have a material adverse effect on our business, cash flow, financial condition or results of operations78% rewritten
84We are subject to risks related to taxation in multiple jurisdictions
85If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
86If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
87Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
88We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met
89We are a “smaller reporting company” and a “non-accelerated filer” and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to smaller reporting companies or non-accelerated filers could make our common stock less attractive to investors
90We do not intend to pay dividends for the foreseeable future
91We could be subject to securities class action litigation

Other Equillium 10-Ks

FY2024 10-K risk factors
89 risks
Clinical-stage biotech focused on itolizumab and immune-modifying therapies, facing substantial ongoing losses and capital raising needs.
Filed Mar 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.